ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

CamreliZumab Plus Carboplatin and PemetreXed as First-Line Treatment for Advanced NonsQuamous NSCLC: EXtended Follow-Up of CameL Phase 3 Trial

Zhou, Caicun; Chen, Gongyan; Huang, Yunchao; Zhou, Jianying; Lin, LiZhu; Feng, Jifeng; Wang, Zhehai; Shu, YongQian; Shi, Jianhua; Hu, Yi; Wang, QiMing; Cheng, Ying; Wu, Fengying; Chen, Jianhua; Lin, Xiaoyan; Wang, Yongsheng; Huang, Jianan; Cui, Jiuwei; Cao, Lejie; Liu, Yunpeng; Zhang, Yiping; Pan, Yueyin; Zhao, Jun; Wang, LiPing; Chang, Jianhua; Chen, Qun; Ren, Xiubao; Zhang, Wei; Fan, Yun; He, Zhiyong; Fang, Jian; Gu, Kangsheng; Dong, XiaoRong; Jin, Faguang; Gao, Hongjun; An, Guangyu复旦大学; 广州医学院; 广州中医药大学; 安徽医科大学; 华中科技大学; 吉林大学; 南昌大学; 上海交通大学; 哈尔滨医科大学; 河北医科大学; 四川大学; 浙江大学; 郑州大学; 同济大学; 中国医科大学; 1; 5
Journal of Thoracic Oncology2023-5DOI: 10.1016/j.jtho.2022.12.017
3被引10阅读
引用收藏
分享

摘要

Introduction: In CameL phase 3 study (ClinicalTrials.gov: NCT03134872), addition of camrelizumab to first-line chemotherapy significantly improved the progression-free survival in patients with stages IIIB to IV nonsquamous NSCLC. Here, we present outcomes after a minimum followup of 43.9 months since last patient randomization.Methods: Eligible patients were randomized 1:1 to 4 to 6 cycles of camrelizumab plus carboplatin and pemetrexed or chemotherapy alone every 3 weeks, followed by maintenance camrelizumab plus pemetrexed or pemetrexed only (n = 205 and 207, respectively). Total camrelizumab exposure was up to 2 years.Results: As of January 31, 2022, camrelizumab plus chemotherapy exhibited substantially improved overall survival over chemotherapy alone (median, 27.1 versus 19.8 mo; hazard ratio = 0.72 [95% confidence interval: 0.57-0.92]). In the chemotherapy-alone group, 95 patients (45.9%) crossed over to camrelizumab monotherapy. After adjustment for crossover, the survival benefit with camre-lizumab plus chemotherapy was more pronounced (adjusted hazard ratio = 0.55 [95% confidence interval: 0.42-0.71]). In camrelizumab plus chemotherapy group, 33 patients completed 2 years of camrelizumab. Objective response rate was 97.0%, with ongoing responses in 17 of the 32 responses (53.1%), and 93.9% (31 of 33) of the patients were alive at data cutoff. Safety profiles were consistent with the previous report, and no obvious evi-dence of cumulative toxicity was found with long exposure to camrelizumab.Conclusions: Camrelizumab plus carboplatin and peme-trexed provides long-term survival benefit over chemo-therapy, with manageable toxicity and remarkable and durable response in patients receiving 2 years of camreli-zumab, further supporting camrelizumab combination as first-line treatment for advanced nonsquamous NSCLC.& COPY; 2023 International Association for the Study of Lung Cancer. Published by Elsevier Inc.

学科与关键词

关键词
ImmunotherapyPD-1CamrelizumabChemo-therapyNonsquamous non-small cell lung cancer
相关
加载中…
  • Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial
    Ren, Shengxiang; Chen, Jianhua; Xu, Xingxiang; Jiang, Tao; Cheng, Ying; Chen, Gongyan; Pan, Yueyin; Fang, Yong; Wang, Qiming; Huang, Yunchao; Yao, Wenxiu; Wang, Rui; Li, Xingya; Zhang, Wei; Zhang, Yanjun; Hu, Sheng; Guo, Renhua; Shi, Jianhua; Wang, Zhiwu; Cao, Peiguo; Wang, Donglin; Fang, Jian; Luo, Hui; Geng, Yi; Xing, Chunyan; Lv, Dongqing; Zhang, Yiping; Yu, Junyan; Cang, Shundong; Yang, Zeyu; Shi, Wei; Zou, Jianjun; Zhou, Caicun*Journal of Thoracic Oncology, 2022, 17(4): 544-557.被引 88
  • First-line camrelizumab plus carboplatin and paclitaxel for advanced squamous non-small cell lung cancer: Updated overall survival results from the phase III CameL-sq trial
    Zhou, C.; Cheng, Y.; Chen, J.; Xu, X.; Chen, G.; Pan, Y.; Fang, Y.; Wang, Q.; Huang, Y.; Yao, W.; Wang, R.; Li, X.; Zhang, W.; Zhang, Y.; Shi, J.; Cao, P.; Wang, D.; Lv, D.; Luo, H.; Yang, Z.European Lung Cancer Congress (ELCC), ELECTR NETWORK, 2022-03-30 To 2022.被引 2
  • Effectiveness and safety of camrelizumab in inoperable or advanced non-small cell lung cancer patients: a multicenter real- world retrospective observational study (CTONG2004-ADV)
    Xu, Chong-Rui; Chen, Qixun; Zhou, Chengzhi; Wu, Lin; Li, Wen; Zhang, Huizhong; Li, Yongsheng; Xu, Fei; Xiong, Jianping; Wang, Qiming; Zhang, Haibo; Jiang, Yuequan; Yin, Haitao; Wu, Qingchen; Dai, Qiangsheng; Hu, Jian; Chen, Jianhua; Zhang, Jian; Wu, Gang; Yin, Jun; Zhao, Jianfu; Liu, Baogang; Shan, Jianzhen; Sheng, Liming; Chen, Qunqing; Han, Zhengxiang; Shi, Huaqiu; Liu, Yimin; Chen, Jun; Wu, Yi-Long*Translational Lung Cancer Research, 2023, 12(1): 127-+.
查看全部 →

发表信息

论文状态
公开发表
期刊
Journal of Thoracic Oncology
发表日期
2023-05
卷期
第 18 卷, 第 5 期
页码
628-639
DOI
10.1016/j.jtho.2022.12.017
语言
ENGLISH
成果收录
SCIE
资助标注
Shanghai Municipal Health Commission Collaborative Innovation Cluster Program [2020CXJQ02]; National Natural Science Foundation of China [82141101]

作者

  • Z

    Zhou, Caicun (第一作者)

  • C

    Chen, Gongyan

查看全部 56 位作者收起作者
  • H

    Huang, Yunchao

  • Z

    Zhou, Jianying

  • L

    Lin, LiZhu

  • F

    Feng, Jifeng

  • W

    Wang, Zhehai

  • S

    Shu, YongQian

  • S

    Shi, Jianhua

  • H

    Hu, Yi

  • W

    Wang, QiMing

  • C

    Cheng, Ying

  • W

    Wu, Fengying

  • C

    Chen, Jianhua

  • L

    Lin, Xiaoyan

  • W

    Wang, Yongsheng

  • H

    Huang, Jianan

  • C

    Cui, Jiuwei

  • C

    Cao, Lejie

  • L

    Liu, Yunpeng

  • Z

    Zhang, Yiping

  • P

    Pan, Yueyin

  • Z

    Zhao, Jun

  • W

    Wang, LiPing

  • C

    Chang, Jianhua

  • C

    Chen, Qun

  • R

    Ren, Xiubao

  • Z

    Zhang, Wei

  • F

    Fan, Yun

  • H

    He, Zhiyong

  • F

    Fang, Jian

  • G

    Gu, Kangsheng

  • D

    Dong, XiaoRong

  • J

    Jin, Faguang

  • G

    Gao, Hongjun

  • A

    An, Guangyu

  • D

    Ding, Cuimin

  • J

    Jiang, Xiaodong

  • X

    Xiong, Jianping

  • Z

    Zhou, Xiangdong

  • H

    Hu, Sheng

  • L

    Lu, Ping

  • L

    Liu, Anwen

  • G

    Guo, Shuliang

  • H

    Huang, Jianjin

  • Z

    Zhu, Chengchu

  • Z

    Zhao, Jian

  • G

    Gao, Beili

  • C

    Chen, Yinglan

  • H

    Hu, Chengping

  • Z

    Zhang, Jian

  • Z

    Zhang, Hongmei

  • Z

    Zhao, Hui

  • T

    Tai, Yanfei

  • M

    Ma, Xinjing

  • S

    Shi, Wei

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417